Mining relational paths in integrated biomedical data by Wild, David J. et al.
Mining Relational Paths in Integrated Biomedical Data
Bing He1, Jie Tang3, Ying Ding1, Huijun Wang2, Yuyin Sun1, Jae Hong Shin2, Bin Chen2, Ganesh
Moorthy4, Judy Qiu2, Pankaj Desai4, David J. Wild2*
1 School of Library and Information Science, Indiana University, Bloomington, Indiana, United States of America, 2 School of Computing and Informatics, Indiana
University, Bloomington, Indiana, United States of America, 3Department of Computer Science and Technology, Tsinghua University, Beijing, China, 4 School of
Pharmacy, University of Cincinnati, Cincinnati, Ohio, United States of America
Abstract
Much life science and biology research requires an understanding of complex relationships between biological entities
(genes, compounds, pathways, diseases, and so on). There is a wealth of data on such relationships in publicly available
datasets and publications, but these sources are overlapped and distributed so that finding pertinent relational data is
increasingly difficult. Whilst most public datasets have associated tools for searching, there is a lack of searching methods
that can cross data sources and that in particular search not only based on the biological entities themselves but also on the
relationships between them. In this paper, we demonstrate how graph-theoretic algorithms for mining relational paths can
be used together with a previous integrative data resource we developed called Chem2Bio2RDF to extract new biological
insights about the relationships between such entities. In particular, we use these methods to investigate the genetic basis
of side-effects of thiazolinedione drugs, and in particular make a hypothesis for the recently discovered cardiac side-effects
of Rosiglitazone (Avandia) and a prediction for Pioglitazone which is backed up by recent clinical studies.
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Introduction
The emerging fields of chemogenomics [1] and systems chemical
biology [2] require examination of critical associations between
individual entities (genes, compounds, etc). Identification of
semantic associations can utilize many of the methods of graph
theory, such as finding shortest paths between entities, and along
with Semantic Web methods forms the basis of our work here.
However, the complex structure of the ontologies involved, the
heterogeneity of the data sources, and sheer size of some of the
datasets make this a non-trivial problem: one requires a highly
efficient and scalable framework to identify semantic associations
in the biomedical field. Additionally, there are usually many linked
paths between two instances; thus providing contextual evaluation
of those different linked paths is also a critical problem.
The Semantic Web provides machine-understandable seman-
tics for resources, establishing a common platform to integrate
heterogeneous data sources, and tools for searching and data
mining these sources in an integrative fashion. Semantic Web
methods have been adopted in various areas of life sciences,
healthcare, and drug discovery [3–4], through various projects
including Chem2Bio2RDF (developed in our labs) [5], Bio2RDF
[6], Linking Open Drug Data (LODD) project [7], and Linked
Life Data, which convert data to a common syntax and specify the
meaning of the data through formal, logic-based ontologies or
schemas. In particular, discovering and ranking complex links and
relationships between resources are critical steps toward knowl-
edge discovery. In the biomedical domain, there is a vital need for
cross-domain data mining. Recent technological and experimental
advances in genomics, compound screening in particular have
resulted in an explosion of public data of chemical compounds,
drugs, genomes, biological molecules, and in scholarly publications
that pertain to these entities. Consequently, new informatics-based
integrative domains have emerged, including cheminformatics [8],
chemogenomics [1] and systems chemical biology [2]. Cheminfor-
matics pertains to the large-scale analysis of chemical structures
and their relationships to biological entities; chemogenomics to the
relationships between chemical compounds and genes or protein
targets, and systems chemical biology to the system-wide
application of these techniques (where the system is a cell or
organism as a whole).
In this paper, we first describe an algorithm for tackling this: a
scalable path finding algorithm that works on RDF (the basis on
describing relationships in the Semantic Web) and an algorithm
based on LDA [9] which we call Bio-LDA, that extracts topics
from large quantities of biomedical literature and gives the
probabilistic distribution of biological terms (e.g., compounds,
diseases, and genes) among different topics, so as to provide
contextual information for those identified semantic associations.
Through the integration of the path finding algorithm and a Bio-
LDA algorithm we have developed for ranking paths using
literature associations [10] with our prior work to develop an
integrated RDF systems chemical biology resource [5], we
demonstrate how important semantic and literature-contextual-
ized paths can be identified and evaluated. We discuss this process
using two biomedical case studies.
In the context of Semantic Web as a whole, the problem of
discovering and reasoning complex relationships between resourc-
es has been studied by many researchers, most of which studied a
specific subset of such relationships, or relationships that bear
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certain properties. Anyanwu et al. [11–13] originally formalized
an important subset of complex relationships called Semantic
Associations that are mainly based on undirected or directed
paths. Anyanwu et al. [11,13] define three types of complex
relationships based on Property Sequence (PS) that is a finite
sequence of properties defined in RDFS: r – Path association
capturing the connectivity feature between two resource; r – Join
association indicating that resources r1 and r2 relate to the same
resource; r – ISO association identifying the similarity between r1
and r2. A following-up work [13] formalized the definition of
semantic associations and presented outlines of two implementa-
tions of r – operator. The first approach is to build a separate r –
query processing layer from a storage system. The r – query
processing layer maintains an index called PathGuide that keeps
the path information among classes extracted from schema.
However, this is not very scalable when a large index size and
number of queries for validation is needed. The second approach
is to use graph algorithms on memory-resident RDF graphs.
However, the RDF graphs are usually too large to fit into memory.
Sheth et al. [14] combined novel academic research and
commercialized semantic web technology to provide capabilities
of semantic association identification. Faloutsos et al. proposed an
algorithm to identify an informative subgraph between two nodes
[15]. Mulla et al. proposed three heuristics to calculate weights of
edges and assigned weights to edges of the RDF graph [16] and
applied the algorithm proposed in [15]. Perry et al. introduced a
system for computing Semantic Associations over distributed RDF
data stores in a peer-to-peer setting [17]. For semantic association
finding in the biomedical domain, Dong et al. described a
prototype system for mining the semantic associations in ontology
structure and search for instances that belong to the nodes and
edges along the identified path through SPARQL [18].
Another approach to the discovery of semantic association is to
use a query language that supports semantic association queries.
Kochut and Janik [19] present SPARQLeR, a novel extension of
the SPARQL query language which adds the support for semantic
path queries. The proposed extension fits seamlessly within the
overall syntax and semantics of SPARQL and allows easy and
natural formulation of queries involving a wide variety of regular
path patterns in RDF graphs. SPARQLeR’s path patterns can
capture many low-level details of the queried associations. Other
similar studies include SPARQ2L, PSPARQL (path RDF query
language) [20].
In the field of topic identification and text mining, since Blei
et al. [9] introduced the LDA model, various extended LDA
models have been used in automatic topic extraction from text
corpora. LDA and its extended models have been broadly used in
many areas including the biomedical domain. Zheng et al. [21]
applied the classic LDA model to protein-related MEDLINE titles
and abstracts and extracted 300 major topics. They further
mapped those topics to Gene Ontology (GO) terms. Blei et al. [22]
examined 5,225 free-text items in the Caenorhabditis Genetic
Center (CGC) Bibliography using the classic LDA model. They
found that the LDA model had better predictive performance than
two standard models (unigram and mixture of unigrams) trained
using the same data. Bundschus et al. [23] presented a Topic-
Concept model, which extends the basic LDA framework to reflect
the generative process of indexing a PubMed abstract with
terminological concepts from an ontology.
In this paper, we propose a scalable path finding algorithm that
can not only detect paths between instances belonging to different
classes but also between instances belonging to the same class. In
addition, we complement the algorithm with a Bio-LDA model
which extracts contextual information on topics of bio-terms,
which helps to evaluate and interpret the semantic associations.
This paper is organized as follows: Section 2 describes the
materials and methods; Section 3 presents the results, including
two case studies; section 4 presents a discussion of the results.
Materials and Methods
2.1 Datasets
The work reported in this paper uses the Chem2Bio2RDF
resource [5]. Chem2Bio2RDF covers 25 biomedical datasets,
grouped into 6 domains, namely chemical (PubChem Compound,
ChEBI, PDB Ligand), chemogenomics (KEGG Ligand, CTD
Chemical, BindingDB, MATADOR, PubChem BioAssay, QSAR,
TTD, DrugBank, ChEMBL, Binding MOAD, PDSP,
PharmGKB), biological (UNIPROT, HGNC, PDB, GI), systems
(KEGG Pathway, Reactome, PPI, DIP), phenotype (OMIM,
Diseasome, SIDER, CTD diseases) and literature (MEDLINE/
PubMed). At the time of writing, the numbers of triples (i.e.
relationships encoded) is about 78 million. Provenance informa-
tion has been added and the data has been linked to LODD and
Bio2RDF [6] using owl:sameAs constructs.
Additionally, biological terms that are found in these datasets
(compounds, drugs, genes, diseases and side-effects; collectively we
call these BioTerms) are identified in scholarly journal abstracts in
PubMed, and these terms are used to link Publications (as
identified by a PubMed ID) with entries in Chem2Bio2RDF
datasets. The BioTerm PubMed-dataset relationships are convert-
ed to RDF triples and integrated with Chem2Bio2RDF. Table 1
gives some statistics on the extracted BioTerms. The data schema
used in our system is designed based on the category of bio-terms
(compound, drug, gene, disease, side effect, pathway) and DTD
(Document Type Definition) provided by National Library of
Medicine (NLM). Bio-term dictionaries are generated from the
following data sources listed in Chem2Bio2RDF: the compound
dictionary is generated from PubChem Synonym with the
PubChem Compound identifier (CID); the drug dictionary is
generated from DrugBank and used DBID as the identifier; the
gene dictionary is generated from the HGNC and used UniprotID
as the identifier; the disease dictionary is generated from the CTD
(the comparative toxicogenomics database) and used MeshID as
the identifier; the side effect dictionary is generated from the Sider
and used UMLSID as the identifier; the pathway dictionary is
generated from the KEGG pathway and used KeggID as the
identifier. We parsed the XML file and extracted the terms based
on the pre-generated dictionaries.
2.2 Algorithm for Pathfinding in RDF data
We have developed a scalable and efficient path finding
algorithm that is designed to find all of the paths between any
two entities in the RDF network. In the area of network analysis,
the task of association search can be formalized as a task of path
search in the graph. Algorithms for shortest path [24–25], efficient
shortest paths in sparse networks [26], top-k shortest paths [27–
28], and near-shortest paths [29] have been proposed. See [30–32]
for overviews. See also [33]. The algorithms for shortest path have
been applied to, for instance, find the best routines of vehicles or
messages, find optimal flows in networks (treated for example in
[34]) and traffic-light networks [35], and find the k most likely state
sequences from the HMM graph given the observed acoustic data
[36].
We are given a semantic network (e.g., Chem2Bio2RDF), which
can be represented as a graph G= (V, E), where vMV represents an
entity in the network; erijME represents a relationship with property
r (e.g., drug interaction) between entities vi and vj; the relationship
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can be directional or bi-directional; the goal of association is to
find relationship sequences from vi to vj. The association here is
defined as: Given a network G= (V, E), the association a(vi, vj) is a sequence
of relationships {eri1, e
r
12, …, e
r
lj} satisfying e
r
m(m+1)ME for m=1, 2, …,
l21, where vi and vj are the source entity and the target entity, respectively.
We assume that no entity will appear on a given association
more than one time. We define the process of association search
from one entity to the other as: Given an association query (vi, vj), where
vi denotes the source entity and vj denotes the target entity. Association search is
to find possible associations {ak(vi, vj)} from vi to vj.
In this paper, we formalize the association search problem as
that of near-shortest associations. We use a two-stage approach for
finding the near-shortest associations. The input is an association
query (vi, vj). The objective is to find list of associations A(vi,
vj) = {ak(vi, vj)}.
By combining the initialization step and the output step, our
approach consists of four steps:
1. Initialization. We formalize the network as a directed graph.
We view each entity as a node and each relationship as an edge
in the directed graph. We create an index for the directed
graph and load the index into memory for the following steps.
2. Shortest association finding. It aims at finding the shortest
associations from all entities vMV\vj in the network to the target
entity vj (including the shortest association from vi to vj with
length Lmin). In a graph, the shortest path between two nodes can
be found using the state-of-the-art algorithms, for example,
Dijkstra algorithm. However, we are dealing with a large-scale
network, where the conventional Dijkstra algorithm results in a
high time complexity of O(n2). We propose using a heap-based
Dijkstra algorithm to quickly find the shortest associations that
can achieve a complexity of O(nlogn).
3. Near-shortest associations finding. Based on the length of
shortest association Lmin found in Step 2 and a pre-defined
parameter b, the algorithm requires enumeration of all
associations that are less than (1+b)Lmin by a depth-first search.
We constrain the length of an association to be less than a pre-
defined threshold. This length restriction can reduce the
computational cost.
The correctness of the approach follows from the obvious
dynamic programming interpretation of Step 2 and Step 3.
Figure 1 summarizes the proposed algorithm. In the rest of the
section, we will explain the two main stages (Step 2 and Step 3).
2.2.1 Algorithm for Shortest Association Finding
In the second step of the approach, we try to find the shortest
associations from all entities (vMV\vj) to the target entity vj. The step
is necessary a_s all of the found shortest associations d9(vi) will be
used to guide the search process in Step 3. Dijkstra is the
traditional approach for the shortest path search in a graph;
however, the conventional Dijkstra algorithm has a complexity of
O(n2), making it inefficient for a large graph. We use a heap-based
Dijkstra algorithm (heap-Dijkstra) which has a complexity of
O(nlog(n)). The heap-Dijkstra is summarized in Figure 2.
In the heap-Dijkstra algorithm, we firstly create a minimal heap.
Then, in each iteration of the algorithm, we use the heap to find
the minimal value. The function is in heap() in line 14 is to
determine whether the node u has been inserted into the heap or
not. The operations ‘‘moveUp’’ and ‘‘insert’’ are respectively used
to resort the heap and to insert a node into the heap. This focuses
on finding the shortest path from each node to a specified target
node. This is different from the traditional use of the Dijkstra
algorithm where the objective is usually to find the shortest path
from a specified source node to each of the other nodes. We
conducted complexity analysis of the algorithm. As all nodes may
be inserted into heap, the complexity of the loop from line 5 is
O(n). In the loop, the algorithm requires enumerating all edges
E(vmin) pointing to the selected node vmin. Usually, we have
|E(vmin)|%|V|, where |E(vmin)| is the number of edges pointing to
the node vmin and |V| is the number of nodes in graph G. In our
research network, the average number of edges pointing to a node
is about 5. Hence, we view the complexity of the loop in line 9 as
O(1). The running time of the operation ‘‘moveUp’’ in line 15 is
log(n), necessitating the operation ‘‘insert’’ in line 17. Therefore,
the final complexity of the algorithm is O(nlog(n)).
More intuitively, search processes starts at the starting node and
ending note at the same time. The process systematically explores
all the neighboring nodes in sequence; then for each of those
nearest neighboring nodes, it visits their unexplored neighbor
nodes and records/updates all those stretching-out paths. The two
processes end when they first explored the same node in the graph.
Thus the shortest path is identified by combining the recorded
path between the staring node and the coincidental node and
between the coincidental node and the ending node. An example
showing how the algorithm runs on Chem2Bio2RDF data are
shown in Figure 3.
In the above example, we want to find the path between node 1
and node 26 (Figure 3-a):
1. Breadth First Search (BFS) explores the nearest neighbor of node
1 and it reaches node 3, 4, 6, 7, 10 (Figure 3-b);
2. Meanwhile, another BFS explores the nearest neighbor of node
26 similarly and it reaches node 19, 21, 23, 24, 25 (Figure 3-c);
3. Explore all the nearest neighbors of node 3, 4, 6, 7, 10, and it
reaches 2, 5, 8, 9, 11, 14, 18 (Figure 3-d);
4. Meanwhile, explore all the nearest neighbors of node 19, 21,
22, 23, 24, 25, and it reaches 15, 16, 18, 22 (Figure 3-e);
Table 1. Statistics of the bio-terms extraction.
Bio-Terms # of unique terms # of term-citation pairs # of unique citations
Compound 56,383 11,775,891 5,856,084
Drug 2,820 5,624,529 3,427,067
Gene 13,022 5,252,844 3,735,517
Disease 3,848 12,612,636 7,066,084
Side Effect 1,363 10,489,676 6,310,741
Pathway 180 916,754 838,090
doi:10.1371/journal.pone.0027506.t001
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5. One node (i.e., node 18) first gets visited by both BFS processes;
algorithm ends. The shortest path between node 1 and node 26
is 1–10–18–21–26 (marked in red in Figure 3-f).
2.2.2 Near-Shortest Association Finding
In the previous step, we obtain the shortest association from each
source entity to the target entity vj, including the shortest association
with the length Lmin from the source entity vi to the target entity vj. In
this step, based on the depth-first search, we try to find the near-
shortest associations. The algorithm runs a straightforward vi-vj
association enumeration algorithm (depth-first search). The depth-
first search itself has an exponential complexity. We apply several
strategies to reduce the computational cost. First we use an indicator
c(v) to avoid loop in the association. Next we utilize the shortest
associations d9(vi) found in Step 2 to prune the search space.
Specifically, we extend an vi-s association to u along the relationship
e= (s, u) if and only if d(s)+1+d9(u),(1+b)Lmin, where d(s) is the length
the current vi-s association and d9(u) is the shortest association from
the entity u to the target entity vj (cf. line 11 in Figure 1).
Whenever an association a(vi, vj) is found using the above
method, we calculate the length of the association d(a(vi, vj)) and
add the association with its length to the association set A. The
search terminates when no more association can be found. Then
we rank all a(vi, vj)MA with the lowest d(a(vi, vj)) on the top. Finally,
we return the ranked associations. It is not easy to accurately
analyze the complexity of the algorithm in this step. Depth-first
search itself has an exponential complexity. However, in our
algorithm we utilized several strategies to heuristically guide the
search. The number of search steps is greatly reduced. An
empirical analysis of the experimental results on the researcher
network (with half million nodes and 2 millions edges) shows that
the average search steps in this sub-process is 14,418 and the
average time cost in this step is 0.34s which takes only 16.49% of
the total time cost (about 3 seconds on average).
2.3 Bio-LDA
Natural language processing (NLP) has been widely used to mine literatures
in biomedical domain [37,38]. Compared to traditional NLP techniques,
which bases on linguistic rules of the documents, modern probabilistic models
Figure 1. Shortest path algorithm. The pseudo code for the shortest path finding algorithm.
doi:10.1371/journal.pone.0027506.g001
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focus on the topical features of the documents. For example, LDA, a
hierarchical Bayesian model, and its assorted variations, can [39,40] capture
groups of words that tend to be used to discuss the same topics. Applications of
LDA in the biomedical domain have already produced promising results
[22,41,42]. However, few of those applications take bio-terms (including
genes, compounds, diseases, etc.) into a customized LDA model as the hidden
variables. The Bio-LDA model used in this paper not only uncover the topical
feature of common words, but more importantly, also the bio-terms. The
similarity of bio-terms are then measured using KL-divergence, which,
compared to the co-occurrence-based methods, is more helpful for identifying
hidden associations [43,44].
The Bio-LDA model extracts latent topics of bio-terms from
biomedical literature, and which further provides semantically
contextual evaluation for those associations identified by the path
finding algorithm.
Our Bio-LDA model extends the ACT model proposed by [45]
as shown in Figure 4. Based on the results of Bio-LDA, we
calculate entropy and KL divergence for any given two RDF
nodes in the RDF graph to identity their semantic association.
The journal information is viewed as a stamp associated with
each word in a paper. Intuitively, the co-occurrence of bio-terms
in a document determines topics in this document and each topic
then generates the words. a,b,m which are the Dirichlet priors for
the distribution of bio-terms over topics, topic over words, and
journals over topics. B is the total set of bio-terms. T denotes the
total set of topics. D is the overall set of documents. Nd is the set of
words in a given document d.
The generative process can be summarized as follows:
1. For each topic z, draw wz and yz respectively from Dirichlet
priors bz and mz;
2. For each word wdi in paper d:
N draw a bio-term xdi from bd uniformly;
N draw a topic zdi from a multinomial distribution hxdi
N specific to bio-term xdi, where h is generated from a Dirichlet
prior a;
N draw a word wdi from multinomial wzdi ;
N draw a journal stamp jdi from multinomial yzdi .
In our model, Gibbs sampling is chosen for inference. As for the
hyperparameters a, b, and m, we take a fixed value (i.e.,
a=50=T, b=0.01, and m=0.1). In the Gibbs sampling
procedure, we first estimate the posterior distribution on just x
and z and then use the results to infer h,w, and y. The posterior
probability is calculated by the following equation:
P(zdi,xdijz{di,x{di,w,j,a,b,m)!
m{dixdizdi
zazdiX
z
(m{dixdiz
zaz)
n{dizdiwdi
zbwdiX
wv
(n{dizdiwv
zbwv )
n{dzdi jd
zmjdX
j
(n{dzdi j
zmj)
ð1Þ
where the superscript 2di denotes a quantity, excluding the
current instance (e.g., the di-th word token in the d-th paper). After
Gibbs sampling, the probability of a word given a topic w, the
probability of a journal given a topic y, and the probability of a
topic given a bio-term h can be estimated as follows:
wzwdi~
n{dizdiwdi
zbwdiX
wv
(n{dizdiwv
zbwv )
, ð2Þ
Figure 2. Heap-Dijkstra algorithm.
doi:10.1371/journal.pone.0027506.g002
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yzjd
~
n{dzdi jd
zmjdX
j
(n{dzdi j
zmj)
, ð3Þ
hxz~
mxzzazX
z0 (mxz0zaz0 )
ð4Þ
3. Bio-term Entropy over Topics
In information theory, entropy is a measure of the
uncertainty associated with a random variable. It is also a
measure of the average information content one is missing
when one does not know the value of random variable. In our
Bio-LDA model, we can compute the bio-term entropies over
topics as shown in equation 5, which indicates that bio-terms
tend to address a single topic or cover multiple topics. The
Figure 3. An intuitive example of the path finding algorithm.
doi:10.1371/journal.pone.0027506.g003
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higher the entropy is, the more diverse the bio-term is over
topics.
Entropy bið Þ~{
XT
z~1
hbizloghbiz ð5Þ
4. Semantic Association
Kullback-Leibler divergence (KL divergence) is a non-symmet-
ric measure of the difference between two probability distributions.
In our Bio-LDA model, we used the KL divergence as the non-
symmetric distance measure for two bio-terms over topics, as
shown in equation 6.
KL bi,bj
 
~
XT
z~1
hbizlog
hbiz
hbjz
ð6Þ
The symmetric distance measure of two bio-terms over topics is
the sum of two non-symmetric distances, as shown in equation 7.
sKL bi,bj
 
~
XT
z~1
hbiz log
hbiz
hbjz
zhbjzlog
hbjz
hbiz
 !
ð7Þ
sKL divergence measures the similarity between two probability
distributions. In our Bio-LDA model, each bio-term is represented by a
probability distribution which designates the strength of the semantic
association between the bio-terms and a set of topics (or research issues).
Thus sKL divergence is used to calculate the similarity between a pair of bio-
terms by means of measuring the similarity between the two probability
distributions associated with each bio-term of the pair. The smaller the sKL
score is, the more semantically relevant the two bio-terms are in terms of their
involvements with a set of research issues. This association score can combined
with the pre-knowledge of bio-terms (i.e. Chem2Bio2Rdf) for novel knowledge
discovery. The score of a given directed semantic association is
simply given by the accumulated distance between bio-terms on a
path, as shown in equation 8. The score of an undirected path is
given by the accumulated symmetric distance between bio-terms,
as shown in equation 9. In this study, we do not evaluate the
direction of the associations, focusing only on the association
score calculated by the symmetric distances. The association
search in Bio-LDA model is finding the associations with the
smallest score.
Results
We implemented the path finding algorithm described in
section 2.2 using C++ and created a tool called associationsearch
which will find paths of given length between any two items in our
Chem2bio2rdf dataset. These items can be compounds, drugs,
genes, pathways, diseases, or side-effects. These paths are then
ranked (i.e., evaluated) by the Bio-LDA model described in section
2.3, and the user can select a maximum number of paths to return.
The paths are then visualized using a flash interface within a
browser.
We present two case studies that apply this method to address
biological research problems.
3.1 Finding gene associations between thiazolinediones
and cardiac side-effects
Insulin-sensitizing drugs from the thiozalinedione class have
revolutionized the treatment of insulin-dependent diabetes yet
have been beset by rare but serious side effects. The drugs
Troglitazone, Rosiglitazone and Pioglitazone are thought to work
Figure 4. Graphical representation of the Bio-LDA. a,b,m are the Dirichlet priors for the distribution of bio-terms over topics, topic over words,
and journals over topics. B is the total set of bio-terms. T denotes the total set of topics. D is the overall set of documents. Nd is the set of words in a
given document d.
doi:10.1371/journal.pone.0027506.g004
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Figure 5. Ranked association graphs between myocardial infarction and Rosiglitazone (top) or Troglitazone (bottom) identify SAA2,
APOE, ADIPOQ, and CYP2C8 genes as significant for Rosiglitazone. The red-outlined box is the starting node and ending node, that is, the bio-
terms associations that we are searching for. Yellow-outlined boxes are the intermediate bio-terms. Other boxes indicate the types of the connection
between the two intermediate bio-terms that it is connected to, which gives a hint on which database this connection is originated from.
doi:10.1371/journal.pone.0027506.g005
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by binding to the PPAR-gamma receptor, one of several nuclear
receptors involved in fatty acid and glucose uptake. However,
these receptors are also known to be involved in much larger scale
regulation and metabolic processes including metabolism of
xenobiotics (foreign substances in the body). Interference of some
of these processes may be responsible for the side effects that have
caused these drugs to ‘‘fall from grace’’: Troglitazone was
withdrawn from the U.S. market in 2000 due to adverse liver
side effects; Rosiglitazone was until recently believed to be safe as it
does not appear to have the hepatic side effects of Trogitazone,
however it was restricted in the U.S. in 2011 and removed from
the European market entirely in September 2010 due to increased
risk of myocardial infarction in patients. Pioglitazone is currently
under review.
We used our algorithms to examine ranked associations
between Rosiglitazone and myocardial infarction, and Troglita-
zone and myocardial infarction, to see if we could identify gene
associations that may account for the cardiac effects of
Rosiglitazone. The association graphs for these two drugs are
shown in Fig. 5. The red-outlined box is the starting node and ending node,
that is, the bio-terms associations that we are searching for. Yellow-outlined
boxes are the intermediate bio-terms. Other boxes indicate the types of the
connection between the two intermediate bio-terms that it is connected to, which
gives a hint on which database this connection is originated from. Note that
Fig. 5 and Fig. 6 are screenshots of the visualization provided by our
application in which users can interactively moving the nodes and clicking the
nodes to obtain more information about the node. The graphs show that
there is a strong ranked association between Rosiglitazone and
myocardial infarction which is not present for Troglitazone,
particularly involving four genes: SAA2 (Serum Amyloid A 2),
APOE (Apolipoprotein E), ADIPOQ (Adiponectin) and CYP2C8
(Cytochrome P450 2C8). Examination of these genes indicates
that all are involved in cardiovascular lipid metabolic processes. In
particular, activation of ADIPOQ results in increased HDL (‘‘good’’
cholesterol) and activation of APOE results in increased LDL levels
(‘‘bad’’ cholesterol), a potential mechanism that would account for
Rosiglitazone’s cardiac side effects as has recently been reported in
the literature [46]. The next obvious question is whether
Pioglitazone interacts with these genes. Association graphs
between Pioglitazone and myocardial infarction (and Pioglitazone
and Rosiglitazone) show strong associations between Pioglitazone
and ADIPOQ, but not with APOE, indicating that Pioglitazone
should increase HDLs but not LDLs. This is confirmed clinically
by recent literature [45].
We further evaluated these relationships by directly examining
the ranked paths from the BioLDA algorithm. Table 2 and 3
shows the symmetric KL divergence for semantic associations for
the two pairs of bio-terms.
3.2 Associations between non-steroidal anti-
inflammatory drugs (NSAIDs), inflammation and
Parkinson Disease
Recent research [47] has shown that use of Ibuprofen, a non-
steroidal anti-inflammatory drug, is clinically associated with
Figure 6. Ranked association graphs between Ibuprofen and Parkinson Disease (top) as well as Aspirin and Parkinson Disease. The
red-outlined box is the starting node and ending node, that is, the bio-terms associations that we are searching for. Yellow-outlined boxes are the
intermediate bio-terms. Other boxes indicate the types of the connection between the two intermediate bio-terms that it is connected to, which gives a hint
on which database this connection is originated from.
doi:10.1371/journal.pone.0027506.g006
Table 2. Symmetric KL divergence for paths between Troglitazone and Myocardial infarction.
Path sKL divergence
Troglitazone,SLC29A1,Dipyridamole,Myocardial-infarction 16.151
Troglitazone,Edema,Iodixanol,Myocardial-infarction 23.105
Troglitazone,Edema,Dipyridamole,Myocardial-infarction 24.086
Troglitazone,Congestive-heart-failure,Bisoprolol,Myocardial-infarction 24.151
Troglitazone,Edema,Bisoprolol,Myocardial-infarction 24.744
Troglitazone,PPARG,Rosiglitazone,Myocardial-infarction 25.454
Troglitazone,Diabetes-Mellitus,-Type,Benazepril,Myocardial-infarction 25.732
Troglitazone,Syncope,Dipyridamole,Myocardial-infarction 26.176
Troglitazone,Hyperglycemia,Rosiglitazone,Myocardial-infarction 26.835
Troglitazone,Syncope,Bisoprolol,Myocardial-infarction 26.953
Troglitazone,Hyperglycemia,Pioglitazone,Myocardial-infarction 27.491
Troglitazone,PPARG,Pioglitazone,Myocardial-infarction 28.126
Troglitazone,Edema,Nicardipine,Myocardial-infarction 28.175
Troglitazone,Edema,Betaxolol,Myocardial-infarction 28.564
Troglitazone,Weight-gain,Bisoprolol,Myocardial-infarction 28.804
Troglitazone,Edema,Fosinopril,Myocardial-infarction 29.052
Troglitazone,Edema,Amoxapine,Myocardial-infarction 29.147
Troglitazone,Edema,Oxaprozin,Myocardial-infarction 29.222
Troglitazone,Malaise,Betaxolol,Myocardial-infarction 29.315
Troglitazone,Edema,Cilazapril,Myocardial-infarction 29.361
doi:10.1371/journal.pone.0027506.t002
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Table 3. Symmetric KL divergence for paths of Rosiglitazone and Myocardial infarction.
Path sKL divergence
Rosiglitazone,Myocardial-infarction 17.231
Rosiglitazone,Congestive-heart-failure,Bisoprolol,Myocardial-infarction 21.085
Rosiglitazone,Heart-failure,Bisoprolol,Myocardial-infarction 22.067
Rosiglitazone,Hyperglycemia,Pioglitazone,Myocardial-infarction 22.411
Rosiglitazone,Hyperglycemia,Cilazapril,Myocardial-infarction 24.814
Rosiglitazone,Hyperglycemia,Betaxolol,Myocardial-infarction 24.892
Rosiglitazone,Hypoglycemia,Bisoprolol,Myocardial-infarction 25.269
Rosiglitazone,Hyperglycemia,Oxaprozin,Myocardial-infarction 25.494
Rosiglitazone,Hyperglycemia,Diazoxide,Myocardial-infarction 25.767
Rosiglitazone,Bilirubinemia,Eletriptan,Myocardial-infarction 26.273
Rosiglitazone,Bilirubinemia,Dolasetron,Myocardial-infarction 26.439
Rosiglitazone,Diabetes-Mellitus,-Type,Benazepril,Myocardial-infarction 26.634
Rosiglitazone,Hyperglycemia,Bosentan,Myocardial-infarction 26.683
Rosiglitazone,Hyperglycemia,Candesartan,Myocardial-infarction 26.688
Rosiglitazone,Hyperglycemia,Quinapril,Myocardial-infarction 27.381
Rosiglitazone,Diabetes-Mellitus,Pioglitazone,Myocardial-infarction 27.821
Rosiglitazone,Hypoglycemia,Betaxolol,Myocardial-infarction 27.832
Rosiglitazone,Hypoglycemia,Pioglitazone,Myocardial-infarction 28.316
Rosiglitazone,Dizziness,Bisoprolol,Myocardial-infarction 28.681
Rosiglitazone,Nasopharyngitis,Bosentan,Myocardial-infarction 28.699
doi:10.1371/journal.pone.0027506.t003
Table 4. Symmetric KL divergence for paths between Ibuprofen and Parkinson Disease.
Paths KL
Ibuprofen PharmGKB CYP2C9 HPRD POR CTD Parkinson-Disease 28.077
Ibuprofen Drugbank PTGS2 CTD-HUGE_Genopedia-HUGE_Phenopedia Parkinson-Disease 33.049
Ibuprofen PharmGKB Hemorrhage HUGE_Phenopedia HSPA1L HUGE_Genopedia-HUGE_Phenopedia Parkinson-Disease 36.573
Ibuprofen PharmGKB CYP2C9 PharmGKB Haloperidol PharmGKB Parkinson-Disease 37.339
Ibuprofen PharmGKB Hemorrhage CTD GABRR1 CTD Parkinson-Disease 37.791
Ibuprofen PharmGKB Hemorrhage HUGE_Phenopedia HSPA4 CTD Parkinson-Disease 37.842
Ibuprofen PharmGKB Hemorrhage CTD HRH1 HUGE_Genopedia-HUGE_Phenopedia Parkinson-Disease 38.153
Ibuprofen PharmGKB Hemorrhage CTD RARG CTD Parkinson-Disease 38.558
Ibuprofen PharmGKB Hemorrhage CTD MAP2K2 CTD Parkinson-Disease 38.858
Ibuprofen PharmGKB Hemorrhage CTD HSPA5 CTD-HUGE_Genopedia-HUGE_Phenopedia Parkinson-Disease 39.055
Ibuprofen PharmGKB Hemorrhage HUGE_Phenopedia MMP8 CTD Parkinson-Disease 39.668
Ibuprofen PharmGKB Hemorrhage HUGE_Phenopedia SCNN1A CTD Parkinson-Disease 39.783
Ibuprofen PharmGKB Hemorrhage CTD GOT1 CTD Parkinson-Disease 39.896
Ibuprofen PharmGKB Hemorrhage HUGE_Phenopedia HSPA1A CTD-HUGE_Genopedia-HUGE_Phenopedia Parkinson-Disease 40.331
Ibuprofen PharmGKB Hemorrhage CTD HSP90B1 CTD Parkinson-Disease 40.886
Ibuprofen PharmGKB Hemorrhage HUGE_Phenopedia IL1A HUGE_Genopedia-HUGE_Phenopedia Parkinson-Disease 41.056
Ibuprofen PharmGKB Hemorrhage HUGE_Phenopedia MMP12 CTD Parkinson-Disease 41.127
Ibuprofen PharmGKB Hemorrhage HUGE_Genopedia-HUGE_Phenopedia SELP CTD Parkinson-Disease 41.278
Ibuprofen PharmGKB Hemorrhage CTD RARB CTD Parkinson-Disease 41.455
Ibuprofen PharmGKB Hemorrhage HUGE_Phenopedia SCGB1A1 CTD Parkinson-Disease 41.47
doi:10.1371/journal.pone.0027506.t004
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reduced risk of Parkinson Disease. This effect is not found with
other painkillers, such as Aspirin and Acetaminophen (Paraceta-
mol). It is speculated that this effect may be due to the anti-
inflammatory effects of Ibuprofen on neuroinflammation. We
performed searches to (i) identify paths containing genes linking
Ibuprofen, inflammation and Parkinson Disease (through three
searches – Ibuprofen-Parkinson Disease, Ibuprofen-inflammation
and inflammation-Parkinson Disease) and (ii) identify genes
associated with Ibuprofen but not with the other NSAIDS (in
case this could be used to account for the differential activity with
Aspirin, etc). Our searching identified 70 genes that are associated
with Ibuprofen, inflammation and Parkinson Disease, 9 of which
are known to be linked to inflammation: IL1A, IL1B, IL1RN, IL6,
LTA, NFKB1, NFKBIA, PTGS2 and TNF.
Of particular note, these searches identified a clear direct
connection between the primary target of Ibuprofen (PTGS2, or
Cox2 – Ibuprofen is a nonspecific inhibitor that also targets Cox1),
and Parkinson Disease. This link maps to experimental data in the
CTD dataset. The Cox2 link is supported by a variety of recent
research [48–52] which indicates that neuroinflammation is
implicated in Parkinson’s Disease, and that the Cox2 gene is
implicated in this inflammation process. Indeed, selective and
nonselective Cox2 inhibitors have been examined for their effect in
this inflammatory process [52]. Selective Cox2 inhibitors may be
of particular interest.
In our second search, we found a single gene, AMBP, which is
differentially associated with Ibuprofen (and not with other
NSAIDS), and which is associated with Parkinson disease (but
not inflammation), based on a 1996 study which showed the
potential of AMBP as a biomarker for the disease [53]. Several of
the results searches are shown in Figure 6. The red-outlined box is the
starting node and ending node, that is, the bio-terms associations that we are
searching for. Yellow-outlined boxes are the intermediate bio-terms. Other boxes
indicate the types of the connection between the two intermediate bio-terms that
it is connected to, which gives a hint on which database this connection is
originated from.
We further evaluated these relationships by directly examining
the ranked paths from the BioLDA algorithm. Table 4 and 5
shows the symmetric KL divergence for semantic associations for
the two pairs of bio-terms. The smaller the KL divergence is, the
more thematically similar the bioterms along the path are in the
literature. In Table 4, the path Ibuprofen-PTGS2-PD ranks high.
Teismann et al. [54] studied the relationship between COX-
2(PTGS2) and Parkinson Disease by MPTP (1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine) model. MPTP induces Parkinson
Disease and COX-2. The authors claimed that COX-2 inhibitors
may be therapies for Parkinson Disease if the inhibitors have
ability to penetrate the blood brain barrier. Many paths that
connect Ibuprofen and Parkinson Disease through Hemorrhage
and other genes have shown small KL divergence. Several studies
have shown that Ibuprofen is helpful in preventing or decreasing
susceptibility to different types of hemorrhage [55–58].
Discussion
In this paper, we propose a scalable path finding algorithm and
a topic model called Bio-LDA so as to mine semantic associations
in integrated platform of various biomedical databases. The path
finding algorithm can identify semantic paths between any two
classes or instances in the linked open data in the biomedical
domain. The Bio-LDA model extracts distributions of topics for
bio-entities, which can provide topic-sensitive ranking of identified
semantic associations. The two use cases presented in the paper
demonstrate the rich possibilities that the proposed algorithm and
Table 5. Symmetric KL divergence for paths between Aspirin and Parkinson Disease.
Paths KL
Aspirin PharmGKB Colorectal-Neoplasms CTD-HUGE_Genopedia-HUGE_Phenopedia CHEK1 CTD Parkinson-Disease 25.682
Aspirin PharmGKB UGT1A6 CTD Parkinson-Disease 26.031
Aspirin PharmGKB Colorectal-Neoplasms CTD-HUGE_Genopedia-HUGE_Phenopedia CASP9 CTD Parkinson-Disease 26.771
Aspirin PharmGKB Colorectal-Neoplasms CTD IKBKB CTD Parkinson-Disease 27.084
Aspirin PharmGKB Colorectal-Neoplasms CTD-HUGE_Genopedia-HUGE_Phenopedia NFKB1 CTD-HUGE_Genopedia-HUGE_Phenopedia Parkinson-Disease 27.437
Aspirin PharmGKB LTC4S HPRD MGST1 CTD Parkinson-Disease 27.678
Aspirin PharmGKB Colorectal-Neoplasms CTD DDIT3 CTD Parkinson-Disease 27.919
Aspirin PharmGKB Colorectal-Neoplasms CTD CCNB2 CTD Parkinson-Disease 27.979
Aspirin PharmGKB Colorectal-Neoplasms CTD-HUGE_Genopedia-HUGE_Phenopedia TFRC CTD Parkinson-Disease 28.226
Aspirin PharmGKB Colorectal-Neoplasms CTD-HUGE_Genopedia-HUGE_Phenopedia GSTA4 CTD-HUGE_Genopedia-HUGE_Phenopedia Parkinson-Disease 28.416
Aspirin PharmGKB Colorectal-Neoplasms c2b2r-CTD-HUGE_Genopedia-HUGE_Phenopedia-PharmGKB MTR CTD-HUGE_Genopedia-HUGE_Phenopedia
Parkinson-Disease
29.2
Aspirin PharmGKB Colorectal-Neoplasms CTD-HUGE_Genopedia-HUGE_Phenopedia NFE2L2 CTD Parkinson-Disease 29.642
Aspirin PharmGKB Colorectal-Neoplasms CTD CCNA2 CTD Parkinson-Disease 29.669
Aspirin PharmGKB Colorectal-Neoplasms CTD RRM2 CTD Parkinson-Disease 30.126
Aspirin PharmGKB Colorectal-Neoplasms CTD-HUGE_Genopedia-HUGE_Phenopedia TGFB1 CTD Parkinson-Disease 30.249
Aspirin PharmGKB Colorectal-Neoplasms CTD-HUGE_Genopedia-HUGE_Phenopedia BCL2L1 CTD Parkinson-Disease 30.357
Aspirin PharmGKB Colorectal-Neoplasms CTD GCLM CTD Parkinson-Disease 30.386
Aspirin PharmGKB Colorectal-Neoplasms CTD MAPK8 CTD Parkinson-Disease 30.58
Aspirin PharmGKB Colorectal-Neoplasms CTD-HUGE_Genopedia-HUGE_Phenopedia HIF1A CTD Parkinson-Disease 30.805
Aspirin PharmGKB Colorectal-Neoplasms CTD-HUGE_Genopedia-HUGE_Phenopedia CHEK1 CTD Parkinson-Disease 25.682
doi:10.1371/journal.pone.0027506.t005
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model can contribute to crucial issues in biomedical domain,
including Polypharmacology, drugs related to inhibition of a
certain gene involved in diseases, and drug-like compounds. The
application discussed in this paper is made available through http://cheminfov.
informatics.indiana.edu:8080/yuysun/hychembiospace.html.
Our path finding algorithm can be readily applied to an
extensible network of linked open data both in the biomedical
domain and other domains. In addition, based on the Bio-LDA
model, we calculate the entropy and KL divergence for genes,
compounds and diseases in the paths. The entropy shows to what
extent the bio-terms are involved in multiple topics among
biomedical literature; the KL divergence indicates the similarity
between two bio-terms involved with different topics. Values
extracted from another knowledge base (Medline) can be further
integrated with user preferences to assign weight to semantic
associations or to rank semantic associations. We also adopt expert
and literature investigation to assess the result and value of the
proposed algorithm, which indicates the algorithm can help
discover invisible knowledge and identify potential research issues
by obtaining and integrating existing knowledge.
For future work, we plan to further explore the potential of
using the knowledge extracted through topic mining model to rank
semantic associations. Moreover, we plan to design a parallel
implementation of Bio-LDA and semantic association finding
algorithm on MPI and MapReduce, which smoothes out storage
and computation bottlenecks. Meanwhile, we would also like to
establish an interactive searching system for semantic associations
based on Chem2Bio2RDF database and extend our algorithm to
incorporate heuristics from user preferences, context, or domain-
specific rules.
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